Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients
- Status
- RECRUITING
- Phase
- N/A
Clinical Trials Related to Melanoma
Related studies linked through entity extraction aliases.
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Holistic Needs Assessments in Patients With Melanoma
- Status
- COMPLETED
- Phase
- N/A
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE2
Mind Over Matter for Black and African American Women: A Single Arm Trial Examining Feasibility and Acceptability of a Supportive Intervention
- Status
- COMPLETED
- Phase
- N/A
A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma
- Status
- COMPLETED
- Phase
- N/A
Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients
- Status
- RECRUITING
- Phase
- N/A
A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma
- Status
- COMPLETED
- Phase
- PHASE1
Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
A Study of GC101 TIL in Advanced Melanoma (BZ)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response
- Status
- RECRUITING
- Phase
- PHASE4
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
A Study of IBI363 in Subjects With Advanced Melanoma
- Status
- RECRUITING
- Phase
- PHASE2
AI-Augmented Skin Cancer Diagnosis in Teledermatoscopy
- Status
- ENROLLING_BY_INVITATION
- Phase
- NA
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2